Actively Recruiting
Trial Evaluating Hypo-fractionated Accelerated Versus Conventional Fractionated Adjuvant RT in Head & Neck Malignancies
Led by All India Institute of Medical Sciences · Updated on 2026-05-07
369
Participants Needed
1
Research Sites
150 weeks
Total Duration
On this page
Sponsors
A
All India Institute of Medical Sciences
Lead Sponsor
I
Indian Council of Medical Research
Collaborating Sponsor
AI-Summary
What this Trial Is About
Hypo-fractionated radiotherapy reduces the OTT (overall treatment time) which may in turn reduce rapid accelerated repopulation of clonogenic cells during waiting period after surgery. If this holds true, there is a potential to achieve better loco-regional control in with PORT for HNSCC. There is a strong radiobiological and economic rationale for delivery hypo-fractionated radiotherapy in HNSCC. The HYPCON III trial will be aimed to reduce the number of fractions by 50% (30 fr to 15 fr)
CONDITIONS
Official Title
Trial Evaluating Hypo-fractionated Accelerated Versus Conventional Fractionated Adjuvant RT in Head & Neck Malignancies
Who Can Participate
Eligibility Criteria
You may qualify if you...
-
Patients with pT1-4 squamous cell carcinoma of oral cavity/ oropharynx/ larynx/ hypopharynx with any of the intermediate risk features:
- Positive lymph node (s)
- Perineural invasion
- Lympho-vascular invasion
- Close margins
-
Age 18-80yrs
-
ECOG performance status 0-1at time of surgery
-
Informed consent
-
Available FOR long term follow-up
You will not qualify if you...
- High risk factors following resection: positive-margin(s)and/or extra nodal extension (ENE)
- pT1-2disease and no high-risk features (LVSI, PNI, Close margins,pN0)
- Patients receiving Neo-adjuvant or concurrent Chemotherapy
- Non-Squamous Histology
- Distant metastasis
- Synchronous or second primary malignancy outside of the oropharynx, oral cavity, larynx and hypopharynx
- Pregnant females or nursing mothers due to the probability of congenital anomalies and potential of this regimen to harm nursing infants.
- Prior Radiotherapy to head and neck region
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Dr. Aman Sharma, Associate Professor, Radiation Oncology, NCI, AIIMS
Jhajjar, Haryana, India
Actively Recruiting
Research Team
D
Dr. Aman Sharma
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here